Artemether/lumefantrine

Artemether/lumefantrine, sold under the trade name Coartem among others, is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum that is not treatable with chloroquine. It is not typically used to prevent malaria. It is taken by mouth.

Common side effects include muscle and joint pains, fever, loss of appetite, and headache. Serious side effects include prolongation of the QT interval. While not well studied, it appears to be safe for use in pregnancy. The dose does not need changing in those with mild or moderate kidney or liver problems.

This combination came into medical use in 1992 and was developed in China. It is on the World Health Organization's List of Essential Medicines. It is not available as a generic medication.

In July 2025 that Swiss regulator Swissmedic have approved artemether-lumefantrine, the first malaria treatment specifically designed for infants and very young children. The medication is expected to gain rapid regulatory clearance in eight African nations participating in its review. Originally introduced in 1999 for broader malaria treatment, Coartem is now approved in a lower-dose formulation tailored for babies weighing under 4.5 kilograms. The new version dissolves easily—even in breast milk—and features a cherry flavor to improve ease of use for caregivers.